ロード中...
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
Triple-negative breast cancer (TNBC) is an aggressive disease that lacks established markers to direct therapeutic intervention. Thus, these tumors are routinely treated with cytotoxic chemotherapies (e.g., anthracyclines), which can cause severe side effects that impact quality of life. Recent stud...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Landes Bioscience
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3409014/ https://ncbi.nlm.nih.gov/pubmed/22751436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.21127 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|